A Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials of Milnacipran Monotherapy in the Treatment of Fibromyalgia

Pain Practice

Volumn 11, Issue 2, 2011, Pages 120-131

  Geisser, Michael E ^a   Palmer, Robert H ^b   Gendreau, R Michael ^c   Wang, Yong ^b   Clauw, Daniel J ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Cypress Bioscience Inc   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Composite responder analysis; Fibromyalgia; Milnacipran; Pain; Pooled analysis

Indexed keywords

MILNACIPRAN; PLACEBO;

ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; NAUSEA; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

EID: 79952299892     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00403.x     Document Type: Article

References (51)

1. Mease P, Arnold LM, Bennett R, etal. Fibromyalgia syndrome. J Rheumatol. 2007;34:1415-1425.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
3. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep. 2005;9:301-306.
4. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007;146:726-734.
5. Abeles M, Solitar BM, Pillinger MH, Abeles AM. Update on fibromyalgia therapy. Am J Med. 2008;121:555-561.
6. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55:320-322.
7. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41:104-113.
8. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15:659-666.
9. Arnold LM. Strategies for managing fibromyalgia. Am J Med. 2009;122:S31-S43.
10. Rao SG. Current progress in the pharmacological therapy of fibromyalgia. Expert Opin Investig Drugs. 2009;18:1479-1493.
11. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004;19(suppl 1):S15-S19.
12. Dubner R, Hargreaves KM. The neurobiology of pain and its modulation. Clin J Pain. 1989;5(suppl 2):S1-S4.
13. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007;8(suppl 2):S63-S74.
14. Pae CU, Marks DM, Shah M, etal. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009;32:355-363.
15. Cates M, Boggs AA, Feldman J. Major depressive disorder. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, eds. Pharmacotherapy Principles & Practice. New York: McGraw-Hill; 2008:569-584.
16. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr. 2009;14:71-73.
17. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8:23-33.
18. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 1996;11(suppl 4):9-14.
19. Pacher P, Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem. 2004;11:925-943.
20. Puozzo C, Lens S, Reh C, etal. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet. 2005;44:977-988.
21. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002;17(suppl 1):S25-S35.
22. Savella (Milnacipran Hydrochloride) Prescribing Information. St. Louis, MO: Forest Pharmaceuticals, Inc.; January 2010.
23. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20:26-33.
24. Mease PJ, Clauw DJ, Gendreau RM, etal. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial [published correction appears in J Rheumatol 2009;36:661]. J Rheumatol. 2009;36:398-409.
25. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published correction appears in Clin Ther 2009;31:446]. Clin Ther. 2008;30:1988-2004.
26. Wolfe F, Smythe HA, Yunus MB, etal. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
27. Sheehan DV, Lecrubier Y, Sheehan KH, etal. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
28. Dworkin RH, Turk DC, Wyrwich KW, etal. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-121.
29. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
30. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14:234-254.
31. Gendreau RM, Thorn MD, Gendreau JF, etal. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975-1985.
32. Arnold LM, Gendreau RM, Spera A, Gendreau J, Wang Y. Milnacipran 100mg/day in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(suppl 10):S527.
33. Ali MW, Talukder E. Analysis of longitudinal binary data with missing data due to dropouts. J Biopharm Stat. 2005;15:993-1007.
34. Prakash A, Risser RC, Mallinckrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract. 2008;62:1147-1158.
35. Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF-ANCOVA in eight clinical trials. BMC Psychiatry. 2004;4:26.
36. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19:227-246.
37. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010;11:180-194.
38. Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A. The clinical importance of changes in the 0 to 10 Numeric Rating Scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain. 2009;11:109-118.
39. Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer RH, Williams DA. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain. 2010;149:373-378.
40. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519-527.
41. Millard RW, Wells N, Thebarge RW. A comparison of models describing reports of disability associated with chronic pain. Clin J Pain. 1991;7:283-291.
42. Vlaeyen JWS, Kole-Snidjers AMJ, Rotteveel AM, Rvesink R, Heuts PHTG. The role of fear of movement/(re)injury in pain disability. J Occup Rehabil. 1995;5:235-252.
43. Geisser ME, Roth RS. Knowledge of and agreement with pain diagnosis: relation to pain beliefs, pain severity, disability, and psychological distress. J Occup Rehabil. 1998;8:73-88.
44. Geisser ME, Wiggert EA, Haig AJ, Colwell MO. A randomized, controlled trial of manual therapy and specific adjuvant exercise for chronic low back pain. Clin J Pain. 2005;21:463-470.
45. Cymbalta (Duloxetine Hydrochloride) Prescribing Information. Indianapolis, IN: Eli Lilly and Company; January 2010.
46. Pristiq (Desvenlafaxine) Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; December 2009.
47. Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151-156.
48. Garcia E, Godoy-Izquierdo D, Godoy JF, Perez M, Lopez-Chicheri I. Gender differences in pressure pain threshold in a repeated measures assessment. Psychol Health Med. 2007;12:567-579.
49. Katz JD, Mamyrova G, Guzhva O, Furmark L. Gender bias in diagnosing fibromyalgia. Gend Med. 2010;7:19-27.
50. Ferrera R, Palmer R, Wang Y, Gendreau R. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from 2 double-blind, dose-controlled extension studies. J Pain. 2009;10(suppl 41):S60.
51. Branco JC, Cherin P, Späth M, Mainguy Y. Long-term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Arthritis Rheum. 2009;60(suppl 10):S529.